Canadian femtech startups build business models around women's healthcare autonomy
By
Madison McLauchlan
Summary
This article explores the rise of Canadian femtech (women's health technology) startups that are building business models centered on women's autonomy and control over their healthcare. It profiles several founders, including Jessica Chalk of myStoria (a menopause-focused platform), and examines how venture capital is increasingly flowing into women's health as a legitimate healthcare and workplace insurance category. The piece highlights the shift from viewing women's health as a niche to recognizing it as core healthcare infrastructure, driven by founders who experienced firsthand how the healthcare and benefits system fails to serve women adequately.
Source
Key quotes
· 3 pulledWe're really seeing this shift to more of women's health as healthcare, workplace insurance, and data infrastructure.
Every founder has an origin story. There's one kind that may resonate with many femtech founders: interacting with a healthcare and benefits system that's not designed to serve her at all.
Often, that experience has been the catalyst to build a product that actually does.
You might also wanna read
MIT Media Lab Working to Advance Women's Health
Experts at HLTH Europe discuss using AI and better data to close the women's health gap
The article reports on discussions at HLTH Europe in Amsterdam about closing the women's health gap through AI and better data. Experts high

Distributed Biomanufacturing: Rethinking Production and Logistics for Autologous Cell Therapies
The Rise of At-Home Vaginal Microbiome Testing: Biohacking, Skepticism, and Unregulated Health Claims
The article explores the growing trend of at-home vaginal microbiome testing kits, driven by biohacker culture and figures like Bryan Johnso

Innovation and Healthcare - the Significance of Hadejia's New Digital Ecosystem
Personal Reflection on Using Proprietary Medical Devices for Diabetes Management
The article discusses the author's personal experience with diabetes and their difficult choice to use a proprietary continuous glucose moni

Comments
Sign in to join the conversation.
No comments yet. Be the first.